Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cosmo Pharmaceuticals NV (COPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3462
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of various gastro-intestinal tract, inflammatory bowel diseases, colon infections and colon diagnosis, among others. Cosmo also provides SIC 8000, a submucosal injectable composition for extracting polyps and adenomas; and other products. The company manufactures products for oral administration such as tablets, capsules, powders and syrups; topical dosage forms such as emulsions, gels, ointments and injectables, among others. Its manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.

Cosmo Pharmaceuticals NV (COPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AIMM Therapeutics Enters Into Co-Development Agreement With Cosmo Pharma 11
Licensing Agreements 12
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 12
Pharmascience Enters into Licensing Agreement with Cosmo Pharma 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 15
Cosmo Pharma Enters into Licensing Agreement with BioMAS 16
Equity Offering 17
Cosmo Pharma Raises USD215.5 Million in Private Placement of Shares 17
Cosmo Pharma Raises USD103.4 Million in private placement of Shares 18
Cassiopea Raises USD186.4 Million in Initial Public Offering of Shares 19
Acquisition 20
Cosmo Pharma Acquires 15.4% Stakes in BioMAS for USD2 Million 20
Cosmo Pharmaceuticals NV – Key Competitors 21
Cosmo Pharmaceuticals NV – Key Employees 22
Cosmo Pharmaceuticals NV – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 26, 2018: Cosmo Half-Year report 2018 24
Corporate Communications 25
May 17, 2017: Cosmo Pharmaceuticals Announces Appointment Of Non-Executive Board Member 25
Legal and Regulatory 26
Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 26
Product News 27
05/18/2017: Salix Pharmaceuticals Announces the Publication of a Study Evaluating the Safety and Efficacy of UCERIS (budesonide) Tablets for Induction of Remission in Patients with Active Mild to Moderate Ulcerative Colitis Refractory to Mesalamine Therapy 27
Product Approvals 28
Nov 01, 2017: Cosmo Pharmaceuticals Provides Update on Commercialization of Rifamycin SV MMX 28
Oct 23, 2017: FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AIMM Therapeutics Enters Into Co-Development Agreement With Cosmo Pharma 11
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 12
Pharmascience Enters into Licensing Agreement with Cosmo Pharma 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 15
Cosmo Pharma Enters into Licensing Agreement with BioMAS 16
Cosmo Pharma Raises USD215.5 Million in Private Placement of Shares 17
Cosmo Pharma Raises USD103.4 Million in private placement of Shares 18
Cassiopea Raises USD186.4 Million in Initial Public Offering of Shares 19
Cosmo Pharma Acquires 15.4% Stakes in BioMAS for USD2 Million 20
Cosmo Pharmaceuticals NV, Key Competitors 21
Cosmo Pharmaceuticals NV, Key Employees 22
Cosmo Pharmaceuticals NV, Subsidiaries 23

List of Figures
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Huawei Technologies Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Huawei Technologies Co., Ltd. (Huawei), a subsidiary of Huawei Investment & Holding Co., Ltd, is an information and communication technology company. The company’s product portfolio includes mobile, broadband, core network, transmission network, and data communication products, besides value …
  • Guadalupe Valley Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Guadalupe Valley Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Xcel Energy Inc:企業の発電所・SWOT分析2018
    Xcel Energy Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (ex …
  • Pact Group Holdings Ltd:企業の戦略・SWOT・財務情報
    Pact Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Pact Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • T3D Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary T3D Therapeutics Inc (T3D) is a developer of solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. It provides a potential to improve …
  • Koninklijke Wessanen N.V.:戦略・SWOT・企業財務分析
    Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sun Pharma Advanced Research Company Ltd (SPARC):企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • Seven Generations Energy Ltd (VII):企業の財務・戦略的SWOT分析
    Seven Generations Energy Ltd (VII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Allan Myers Inc:企業の戦略・SWOT・財務情報
    Allan Myers Inc - Strategy, SWOT and Corporate Finance Report Summary Allan Myers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Progenics Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Progenics Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Progenics Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Peako Ltd (PKO):石油・ガス:M&Aディール及び事業提携情報
    Summary Peako Ltd (Peako), formerly Peak Oil & Gas Ltd, is an oil and gas, and mineral exploration company. The company carries out the business of acquisition, exploration, and development of oil, natural gas, petroleum, and uranium properties. Its projects include SC6C Cadlao and Sunday Creek proj …
  • IDACORP, Inc.:企業の戦略・SWOT・財務分析
    IDACORP, Inc. - Strategy, SWOT and Corporate Finance Report Summary IDACORP, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sinclair Broadcast Group Inc (SBGI):企業の財務・戦略的SWOT分析
    Summary Sinclair Broadcast Group Inc (Sinclair) is a television broadcasting service provider that owns and operates television programs. The company's service portfolio includes content creation, distribution platforms, advertising platform and technical solutions. It offers content across various …
  • Industrial Bank Co., Ltd.:企業の戦略・SWOT・財務情報
    Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • W. L. Gore & Associates Inc:医療機器:M&Aディール及び事業提携情報
    Summary W. L. Gore & Associates Inc (Gore) is a manufacturer and distributor of fluoropolymer products. Its product portfolio includes consumer products, cables, electronic components, fabrics, fibers, medical, pharmaceutical, sealing and vents. The company has developed numerous products for medica …
  • Fujifilm Holdings Corp (FUJIY):企業の財務・戦略的SWOT分析
    Fujifilm Holdings Corp (FUJIY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ingles Markets Inc:企業の戦略・SWOT・財務分析
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • U.S. Army Institute of Surgical Research:医療機器:M&Aディール及び事業提携情報
    Summary U.S. Army Institute of Surgical Research (USAISR), a subsidiary of U.S. Army, is a medical research center that offers solutions for burn, trauma, and combat casualty care from time of injury to rehabilitation. The center conducts research in the areas of dental and trauma research detachmen …
  • Pear Therapeutics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆